The Latest
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
AstraZeneca has now inked four licensing pacts with Chinese drugmakers since the start of 2025, trailing only Roche among major pharmaceutical companies over that timeframe.
Updated 2 hours ago -
Getty Images
News roundupPrime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
An arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for reviews.
-
Alamy
Trump administration5 FDA decisions to watch in the third quarter of 2026
A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.
-
Permission granted by Vertex
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.
-
Getty Images
Obesity drugsKailera says obesity pill succeeds in late-stage trial in China
The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.
-
Getty Images
Emerging biotechCancer, immune drugmakers dominate VC funding so far in 2026
Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.
-
Permission granted by Novartis
Novartis to acquire ADC developer in a deal worth up to $1.5B
The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
Including Vertex’s buyout of Crinetics, four biotech M&A deals this year have involved at least $10 billion in guaranteed proceeds, already matching 2025’s total.
Updated July 6, 2026 -
Getty Images
Oberland pours up to $400M into MeiraGTx eye gene therapies
The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J.
-
Alamy
Gene editingGene editing developer Scribe plots an IPO
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.
-
Getty Images
Beyond Boston: Unlikely cities stake biotech claims
As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
-
Getty Images
A PureTech startup banks $180M for a new IPF drug
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
-
Getty Images
Roche KRAS drug succeeds in head-to-head lung cancer study
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
-
Getty Images
News roundup
BridgeBio gets funding for drug launch; United buys into cell therapy
Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
This year’s IPO class has already accounted for five of the six largest new biotech stock offerings since the start of 2022, according to BioPharma Dive data.
Updated June 17, 2026 -
Courtesy of Ipsen
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.
-
Getty Images
At BIO, tension over China biotech deal regulation looms
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.
Updated July 1, 2026 -
Alamy
Top FDA gene and cell therapy regulator to step down
Following Vijay Kumar’s exit, acting CBER Director Karim Mikhail will also oversee a review office that has become a battleground for debates on FDA flexibility.
-
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive // Emerging biotechBiotech startups are built on venture capital. Track funding rounds here.
Immune drugmakers carried the majority of venture financing in the second half of June, bringing in $608 million in total across five companies, according to BioPharma Dive data.
Updated June 30, 2026 -
ASCO / Nick Agro
The top biopharma conferences remaining in 2026
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for the rest of 2026.
Updated June 25, 2026 -
Getty Images
Abivax shares surge as worries subside over immune drug’s cancer risk
According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.
-
Permission granted by Alkermes
Q&AAlkermes’ incoming CEO has a plan to outplay Lilly and Takeda
Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.
-
Getty Images
Viridian may have edge over Amgen in eye drug showdown, analysts argue
The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.
-
Getty Images
News roundup
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
-
Getty Images
Theravance, after clinical setbacks, agrees to $929M buyout
The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.
